Therapeutic promise and challenges of targeting DLL4/NOTCH1
2011
Targeting DLL4/NOTCH1 for Cancer Treatment
publication
Evidence: moderate
Author Information
Author(s): Yan Minhong
Primary Institution: Genentech, Inc.
Hypothesis
Can targeting the DLL4/NOTCH1 signaling pathway improve cancer therapies?
Conclusion
Targeting DLL4/NOTCH1 signaling shows promise in inhibiting tumor growth but raises safety concerns.
Supporting Evidence
- DLL4 is essential for vascular development and tumor angiogenesis.
- Blockade of DLL4/NOTCH1 signaling leads to chaotic angiogenesis.
- Targeting DLL4/NOTCH1 can enhance the effects of anti-VEGF therapies.
- Safety concerns include liver toxicity and potential for skin lesions.
- Selective inhibition of DLL4 may avoid some toxicities associated with pan-Notch inhibitors.
Takeaway
Scientists are studying a way to block a specific pathway in cancer that helps tumors grow, but it might also cause some side effects.
Methodology
The review discusses various studies and findings related to DLL4/NOTCH1 signaling in cancer.
Potential Biases
Concerns about on-target toxicity and the effects of prolonged treatment with DLL4 inhibitors.
Limitations
The review highlights potential safety issues and the need for careful monitoring in clinical settings.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website